Isopranoid- and dipalmitoyl-aminophospholipid adjuvants impact differently on longevity of CTL immune responses.
The success of lipid membranes as cytotoxic T-cell (CTL) adjuvants requires targeted uptake by antigen-presenting cells (APCs) and delivery of the antigen cargo to the cytosol for processing. To target the phosphatidylserine (PS) receptor of APCs, we prepared antigen-loaded liposomes containing dipalmitoylphosphatidylserine and archaeal lipid liposomes (archaeosomes), containing an equivalent amount of archaetidylserine, and compared their ability to promote short and long-term CTL activity in animals. CTL responses were enhanced by the incorporation of PS into phosphatidylcholine/cholesterol liposomes and, to a lesser extent, into phosphatidylglycerol/cholesterol liposomes, that correlated to the amount of surface amino groups reactive with trinitrobenzoyl sulfonate. Archaeosomes contrasted to the liposome adjuvants by exhibiting higher amounts of surface amino groups and inducing superior shorter and, especially, longer-term CTL responses. The incorporation of dipalmitoyl lipids into archaeosomes induced instability and prevented long-term, but not short-term, CTL responses in mice. The importance of glycero-lipid cores (isopranoid versus dipalmitoyl) to the longevity of the CTL response achieved was shown further by incorporating dipalmitoyl phosphatidylethanolamine (DPPE) or equivalent amounts of synthetic archaetidylethanolamine (AE) into archaeosome adjuvants. Both DPPE and AE at equivalent (5 mol%) concentrations enhanced the rapidity of CTL responses in mice, indicating the importance of the head group in the short term. In the longer term, 5% of DPPE (but not 5% of AE) was detrimental. In addition to head-group effects critical to the potency of short-term CTL responses, the longer term CTL adjuvant properties of archaeosomes may be ascribed to stability imparted by the archaeal isopranoid core lipids.
Dicaire
Chantal J
CJ
National Research Council, Institute for Biological Sciences, Ottawa, Ontario, Canada.
Yu
Siu H
SH
Whitfield
Dennis M
DM
Sprott
G Dennis
GD
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology; D001105:Archaea / Q000737:chemistry; D001672:Biocompatible Materials / Q000737:chemistry / Q000378:metabolism; D005260:Female; D008081:Liposomes / Q000737:chemistry / Q000276:immunology; D008422:Materials Testing; D051379:Mice; D008810:Mice, Inbred C57BL; D015394:Molecular Structure; D010743:Phospholipids / Q000138:chemical synthesis / Q000737:chemistry / Q000276:immunology; D011956:Receptors, Cell Surface / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects / Q000276:immunology
D000276:Adjuvants, Immunologic; D001672:Biocompatible Materials; D008081:Liposomes; D010743:Phospholipids; D011956:Receptors, Cell Surface; C408123:phosphatidylserine receptor